Cleared Abbreviated

K140539 - AERO BLUE PERFORMANCE SURGICAL GOWN (FDA 510(k) Clearance)

Class II General Hospital device cleared through the Abbreviated 510(k) pathway - typically does not require clinical trials.

K140539 · Kimberly Clark Corporation · General Hospital

Download Printable Device Report (PDF)

Optimized for regulatory review, auditing and printing

Jun 2014

Decision

97d

Days

Class 2

Risk

K140539 is an FDA 510(k) clearance for the AERO BLUE PERFORMANCE SURGICAL GOWN. Classified as Gown, Surgical (product code FYA), Class II - Special Controls.

Submitted by Kimberly Clark Corporation (Roswell, US). The FDA issued a Cleared decision on June 9, 2014 after a review of 97 days - within the typical 510(k) review window.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 878.4040 - the FDA general hospital device framework. The Abbreviated 510(k) pathway was used, relying on FDA-recognized standards to demonstrate substantial equivalence.

Device pattern: Standards-based predicate clearance. Standards-verified equivalence. The Abbreviated pathway signals strong alignment with FDA-recognized performance standards - typically associated with lower review burden and faster clearance cycles.

View all Kimberly Clark Corporation devices

Submission Details

510(k) Number	K140539 FDA.gov
FDA Decision	Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received	March 04, 2014
Decision Date	June 09, 2014
Days to Decision	97 days
Submission Type	Abbreviated
Review Panel	General Hospital (HO)
Summary	Summary PDF
Third-party Review	No - reviewed directly by FDA

Regulatory Context

Review time vs. panel average

31d faster than avg

Panel avg: 128d · This submission: 97d

Pathway characteristics

Standards-based clearance path.

Device Classification

Product Code	FYA Gown, Surgical
Device Class	Class 2 - Special Controls
CFR Regulation	21 CFR 878.4040

What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General Hospital devices follow this clearance model.